Incyte is
searching for talented Ph.D. chemists seeking a career in medicinal
chemistry. Candidates with strong synthetic and mechanistic
experience gained from research in total synthesis, diversity-oriented synthesis,
chemical biology or synthetic methodology are highly desired. Our team of
~40 medicinal chemists is highly experienced with the majority having over 15
years in the pharmaceutical industry. The successful candidate will be
engaged in the design and synthesis of novel small molecule inhibitors directed
toward oncology targets at Incyte.
The FDA approval
and successful launch of our first internally invented and developed small
molecule Janus Kinase inhibitor, Jakafi®, in 2011 has been transformative to
our company. In just the past three years, Incyte has evolved from a
small biotechnology company to a mid-stage biopharmaceutical company with over
550 employees in R&D, sales and marketing. Our pipeline is robust
with seven unique new chemical entities that are being studied in over 70 human
clinical trials. 2014 has been a particularly exciting year for us with
the sNDA filing of Jakafi for Polycythemia Vera (PV) and early proof of concept
of our first-in-class small molecule IDO inhibitor INCB24360 as a novel
immunotherapy treatment for melanoma. In addition, we are eager to move
into our beautiful new research building here in Wilmington, DE this fall.
Please have
students who are interested in a career in drug discovery within our growing
and dynamic biopharmaceutical company send their CVs and research summaries to
me at aguntz@incyte.com
If you have any
additional questions, please do not hesitate to contact me directly.
Anne Guntz
Associate Director, Human Resources
Incyte Corporation
Experimental Station
Route 141 and Henry Clay Road
Building E336/104
Wilmington, DE 19880
Phone: 302-498-6906
Fax: 302-425-2774
(Confidential)
This is such a great resource that you are providing and you give it away for free.
ReplyDeletelos angeles biogenetics